Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.
Zacks Small Cap Research on MSN
COCP: CDI-988 Showcased at Calicivirus Conference; Direct Offering Raises Up to $13 Million…
COCP READ THE FULL COCP RESEARCH REPORT Business Update CDI-988 Overview Presented at Calicivirus Conference On September 12, 2025, Cocrystal Pharma Inc. (NASDAQ:COCP) announced that its Presidents ...
The dosing regimen for Zemaira is weight-based so the introduction of larger vial sizes reduces the number of reconstituted vials needed per dose. Zemaira (alpha 1-proteinase inhibitor [human]) is now ...
ResVita Bio, a biotechnology company pioneering continuous protein therapy for skin diseases, today announced the successful ...
A new broad-spectrum coronavirus antiviral, ASAP-0017445, has been nominated as a pre-clinical drug candidate by the Drugs ...
There are currently no approved vaccines or treatments for norovirus infection Cocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback